GSA Capital Partners LLP Has $396,000 Stock Holdings in Sarepta Therapeutics, Inc. $SRPT

GSA Capital Partners LLP reduced its holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 67.2% in the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 20,565 shares of the biotechnology company’s stock after selling 42,060 shares during the quarter. GSA Capital Partners LLP’s holdings in Sarepta Therapeutics were worth $396,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. Vanguard Group Inc. grew its stake in shares of Sarepta Therapeutics by 18.1% in the third quarter. Vanguard Group Inc. now owns 10,817,446 shares of the biotechnology company’s stock worth $208,452,000 after purchasing an additional 1,657,267 shares during the last quarter. Aberdeen Group plc grew its position in shares of Sarepta Therapeutics by 59.6% in the 3rd quarter. Aberdeen Group plc now owns 1,982,764 shares of the biotechnology company’s stock valued at $38,208,000 after buying an additional 740,360 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of Sarepta Therapeutics by 3.0% in the second quarter. Geode Capital Management LLC now owns 1,875,997 shares of the biotechnology company’s stock valued at $32,085,000 after buying an additional 55,076 shares during the period. Federated Hermes Inc. increased its stake in shares of Sarepta Therapeutics by 347.8% in the second quarter. Federated Hermes Inc. now owns 1,308,199 shares of the biotechnology company’s stock valued at $22,370,000 after buying an additional 1,016,069 shares during the period. Finally, Norges Bank bought a new position in shares of Sarepta Therapeutics during the second quarter worth about $15,619,000. Institutional investors own 86.68% of the company’s stock.

Sarepta Therapeutics Trading Up 0.7%

NASDAQ:SRPT opened at $18.97 on Thursday. Sarepta Therapeutics, Inc. has a 12 month low of $10.41 and a 12 month high of $109.55. The company has a current ratio of 2.95, a quick ratio of 1.79 and a debt-to-equity ratio of 0.78. The stock has a market capitalization of $1.99 billion, a price-to-earnings ratio of -6.30, a PEG ratio of 0.47 and a beta of 0.39. The firm has a fifty day simple moving average of $20.57 and a two-hundred day simple moving average of $20.24.

Insider Activity at Sarepta Therapeutics

In related news, COO Ian Michael Estepan sold 13,187 shares of the business’s stock in a transaction dated Tuesday, December 16th. The stock was sold at an average price of $22.31, for a total value of $294,201.97. Following the completion of the sale, the chief operating officer directly owned 193,300 shares of the company’s stock, valued at $4,312,523. The trade was a 6.39% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 7.60% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of analysts have weighed in on the stock. Barclays assumed coverage on shares of Sarepta Therapeutics in a research report on Wednesday, January 28th. They set an “equal weight” rating and a $20.00 target price for the company. Wedbush upped their price objective on shares of Sarepta Therapeutics from $32.00 to $34.00 and gave the company an “outperform” rating in a research note on Friday, January 23rd. Wall Street Zen cut shares of Sarepta Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, November 8th. Guggenheim dropped their target price on shares of Sarepta Therapeutics from $22.00 to $19.00 and set a “buy” rating on the stock in a report on Wednesday, November 5th. Finally, Wells Fargo & Company cut their price target on shares of Sarepta Therapeutics from $50.00 to $45.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 5th. Nine research analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and six have given a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $33.84.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.